Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
9 Jan 24
8-K
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
14 Nov 23
8-K
Nuvalent Announces Pricing of Public Offering of Common Stock
17 Oct 23
8-K
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
13 Oct 23
8-K
Other Events
4 Oct 23
8-K
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Jun 23
8-K
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
11 May 23
8-K
Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
16 Mar 23
Registration and prospectus
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
17 Oct 23
424B5
Prospectus supplement for primary offering
16 Oct 23
S-8
Registration of securities for employees
16 Mar 23
S-3ASR
Automatic shelf registration
16 Mar 23
424B5
Prospectus supplement for primary offering
1 Nov 22
424B5
Prospectus supplement for primary offering
1 Nov 22
424B5
Prospectus supplement for primary offering
31 Oct 22
424B5
Prospectus supplement for primary offering
17 Aug 22
S-3
Shelf registration
10 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
PRE 14A
Preliminary proxy
13 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
Other
EFFECT
Notice of effectiveness
17 Aug 22
CORRESP
Correspondence with SEC
12 Aug 22
UPLOAD
Letter from SEC
11 Aug 22
EFFECT
Notice of effectiveness
29 Jul 21
CERT
Certification of approval for exchange listing
28 Jul 21
SEC STAFF LETTER
SEC staff letter
28 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
CORRESP
Correspondence with SEC
26 Jul 21
CORRESP
Correspondence with SEC
22 Jul 21
UPLOAD
Letter from SEC
21 Jul 21
Ownership
4
Matthew Shair
24 Apr 24
4
Matthew Shair
17 Apr 24
4
Emily Conley
17 Apr 24
4
Matthew Shair
10 Apr 24
4
Deborah Ann Miller
5 Apr 24
4
Matthew Shair
3 Apr 24
SC 13D/A
Bain Capital Life Sciences Fund II, L.P.
29 Mar 24
4
Andrew A. F. Hack
29 Mar 24
4
Deborah Ann Miller
29 Mar 24
144
Notice of proposed sale of securities
28 Mar 24